Associate Professor
Department of Structural and Functional Biology
Via A. da Giussano, 10/12 – Busto Arsizio (Varese), Italy
Tel: +39 0331 339415
Fax: +39 0331 339459
E-mail: elena.monti@uninsubria.it

Prof. Elena Monti received her Degree in Biology (1980) and her Ph.D. in Pharmacology (1984) at the University of Milan. Positions held and dates: Senior Research Technician at the Institute of Pharmacology of the University of Milan School of Sciences (1985-92); Visiting Associate at the Clinical Pharmacology Branch of the National Cancer Institute, National Institutes of Health (Bethesda, USA) (1991); Research Associate at the Institute of Pharmacology of the University of Milan School of Sciences (1992-98); Associate Professor of Pharmacology at the University of Insubria (1998 to present). Member of the American Association for Cancer Research, of the Italian Pharmacological Society and of the Italian Association for Cell Cultures. Prof. Monti is co-author of about 70 full papers in Medline-based journals and of about 60 communications at National and International Meetings.

1. Monti E, Gariboldi MB, Maiocchi A, Marengo E, Cassino C, Gabano E, Osella D. Cytotoxicity of Platinum(II) Conjugate Models. The Effect of Chelating Arms and Leaving Groups on Cytotoxicity: a QSAR Approach. J Med Chem 48:857-866, 2005.

2. Ravizza R, Gariboldi MB, Passarelli L, Monti E. Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin. BMC Cancer 4:92 (online publication), 2004.

3. Ravizza R, Cereda E, Monti E, Gariboldi MB. The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells. Int J Oncol, 25:1817-1822, 2004.

4. Banfi S, Caruso E, Caprioli S, Mazzagatti L, Canti G, Ravizza R, Gariboldi MB, Monti E. Photodynamic effects of porphyrin and chlorin photosensitizers in human colon adenocarcinoma cells. Bioorg Med Chem, 12: 4853-4860, 2004.

5. Gariboldi MB, Ravizza R., Petterino C., Castagnaro M., Finocchiaro G., Monti E. The piperidine nitroxide Tempol as a potential new agent for the therapy of gliomas: in vitro and in vivo effects. Eur J Cancer 39: 829-837, 2003

6. Gariboldi MB, Ravizza R., Riganti L., Meschini S., Calcabrini A., Marra M., Arancia G., Dolfini E., Monti E. Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines. Int J Oncol 22: 1057-1064, 2003

7. Gariboldi MB, Ravizza R., Petterino C., Castagnaro M., Finocchiaro G., Monti E. The piperidine nitroxide Tempol as a potential new agent for the therapy of gliomas: in vitro and in vivo effects. Eur J Cancer 39: 829-837, 2003

8. Monti E., Supino R, Colleoni M., Costa B., Ravizza R., Gariboldi M.B. Nitroxide TEMPOL impairs mitochondrial function and induces apoptosis in HL60 cells.J Cell Biochem 82: 271-276, 2001

9. Gariboldi MB, Ravizza R., Marras E., Perletti G., De Simone A., Piccinini F, Monti E. Resistance of human leukemic cell lines to 1-ß-D-arabinofuranosylcytosine: characterization of an experimental model. Int J Oncol 18: 12345-1249, 2001

10. Meschini S., Calcabrini A., Monti E., Del Bufalo D., Stringaro A., Dolfini E., Arancia G. Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells. Int J Cancer, 87: 615-628, 2000

11. Gariboldi M.B., Rimoldi V., Supino R., Favini E., Monti E. The piperidine nitroxide Tempol induces cell death and p21 WAF1/CIP1 expression through oxidative stress in HL60 cells. Free Rad Biol Med 29:633-641, 2000

12. Minotti G., Cairo G., Monti E. Role of Iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J 13: 199-212, 1999

13. Gariboldi M.B., Lucchi S., Caserini C., Supino R., Oliva C., Monti E. Antiproliferative effect of the piperidine nitroxide TEMPOL on neoplastic and nonneoplastic mammalian cell lines. Free Rad Biol Med 24: 913-923, 1998

14. Dolfini E., Dasdia T., Arancia G., Molinari A., Calcabrini A., Scheper RJ, Flens M.J., Gariboldi M.B., Monti E. Characterization of a clonal human colon adenocarcinoma line intrinsically resistant to doxorubicin. Br. J. Cancer 76: 67-76, 1997

15. Monti E, Cova D, Guido E; Morelli R, Oliva C. Protective effect of the nitroxide TEMPOL against the cardiotoxicity of adriamycin. Free Rad Biol Med 21: 463-470, 1996

16. Perletti G.P., Monti E. PKCs: transducers of critical signals in cancer cells. (Review) Int J Oncol 9: 171-177, 1996

17. Piccinini F, Bradamante S, Monti E, Zhang Y-K, Janzen EG. Pharmacological action of a new spin trapping compound, 2-phenyl-DMPO, in the adriamycin-induced cardiotoxicity. Free Rad Res 23: 81-87, 1995

18. Monti E, Mimnaugh EG, Sinha BK. Synergistic antiproliferative action of etoposide and interleukin-1? is not due to DNA damage in human melanoma cells. Biochim Biophys Acta 1180: 231-235, 1993

19. Monti E, Mimnaugh EG, Sinha BK. Synergistic antiproliferative effects of interleukin-1? and doxorubicin against a human ovarian carcinoma cell line (NIH:OVCAR-3). Biochem Pharmacol 45: 2099-2107, 1993

20. Bradamante S, Monti E, Paracchini L, Piccinini F. Protective activity of the spin trap tert butyl a-phenylnitrone (PBN) in reperfused rat heart. J Mol Cell Cardiol 24: 375-386, 1992

21. Donella Deana A, Monti E, Pinna LA. Inhibition of tyrosine protein kinases by the antineoplastic agent adriamycin. Biochem Biophys Res Commun 160: 1309 1315, 1989

22. radamante S, Monti E, Paracchini L, Perletti G. Hypoxia as a risk factor for doxorubicin induced cardiotoxicity: a NMR evaluation. Biochem Biophys Res Commun 163: 682 688, 1989

23. Monti E, Piccinini F, Favalli L, Villani F. Role of the fast exchanging calcium compartment in the early cardiotoxicity of anthracycline analogs. Biochem Pharmacol 32: 3303 3306, 1983